These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 28582028)

  • 21. Current concepts on cardiovascular stent devices.
    Neamtu I; Chiriac AP; Diaconu A; Nita LE; Balan V; Nistor MT
    Mini Rev Med Chem; 2014; 14(6):505-36. PubMed ID: 24873819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optical coherence tomography (OCT) in PCI for in-stent restenosis (ISR): rationale and design of the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) study.
    Adriaenssens T; Dens J; Ughi G; Coosemans M; Onsea K; Dubois C; Sinnaeve P; Vrolix M; Desmet W
    EuroIntervention; 2011 May; 7 Suppl K():K100-5. PubMed ID: 22027717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.
    Kandzari DE; Mauri L; Koolen JJ; Massaro JM; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    Lancet; 2017 Oct; 390(10105):1843-1852. PubMed ID: 28851504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial.
    Fajadet J; Wijns W; Laarman GJ; Kuck KH; Ormiston J; Münzel T; Popma JJ; Fitzgerald PJ; Bonan R; Kuntz RE;
    Minerva Cardioangiol; 2007 Feb; 55(1):1-18. PubMed ID: 17287679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial.
    Stone GW; Ellis SG; Cannon L; Mann JT; Greenberg JD; Spriggs D; O'Shaughnessy CD; DeMaio S; Hall P; Popma JJ; Koglin J; Russell ME;
    JAMA; 2005 Sep; 294(10):1215-23. PubMed ID: 16160130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Colombo A; Moses JW; Morice MC; Ludwig J; Holmes DR; Spanos V; Louvard Y; Desmedt B; Di Mario C; Leon MB
    Circulation; 2004 Mar; 109(10):1244-9. PubMed ID: 14981005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial.
    Stella PR; Belkacemi A; Dubois C; Nathoe H; Dens J; Naber C; Adriaenssens T; van Belle E; Doevendans P; Agostoni P
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1138-46. PubMed ID: 22422607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-eluting versus bare-metal coronary stents: where are we now?
    Amoroso NS; Bangalore S
    J Comp Eff Res; 2012 Nov; 1(6):501-8. PubMed ID: 24236469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioresorbable Stents in PCI.
    Lindholm D; James S
    Curr Cardiol Rep; 2016 Aug; 18(8):74. PubMed ID: 27312934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravascular ultrasound-guided percutaneous coronary interventions in contemporary practice.
    Bonello L; De Labriolle A; Lemesle G; Roy P; Steinberg DH; Pichard AD; Waksman R
    Arch Cardiovasc Dis; 2009 Feb; 102(2):143-51. PubMed ID: 19303582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experience with Endeavor stent implantations.
    Lupkovics G; Kenéz A; Németh Z; Motyovszki A; Takács I; Papp E
    Coron Artery Dis; 2008 Sep; 19(6):421-3. PubMed ID: 18955836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of human in-stent restenosis: a molecular view.
    Giordano A; Romano A
    Curr Opin Pharmacol; 2011 Aug; 11(4):372-7. PubMed ID: 21497134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden.
    James SK; Stenestrand U; Lindbäck J; Carlsson J; Scherstén F; Nilsson T; Wallentin L; Lagerqvist B;
    N Engl J Med; 2009 May; 360(19):1933-45. PubMed ID: 19420363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding the drug-eluting stent trials.
    Coolong A; Kuntz RE
    Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
    Stone GW; Moses JW; Ellis SG; Schofer J; Dawkins KD; Morice MC; Colombo A; Schampaert E; Grube E; Kirtane AJ; Cutlip DE; Fahy M; Pocock SJ; Mehran R; Leon MB
    N Engl J Med; 2007 Mar; 356(10):998-1008. PubMed ID: 17296824
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.